Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

NCT02410863 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped lack of recruitment due to changed therapy options

Conditions

Malignant Melanoma

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Prof. Dr. med. Dirk Schadendorf